GLAXF News and Press, GlaxoSmithKline Plc From 07/04/22

Unilever's brands are positioned well to navigate whatever is to come economically, it has already grown 7.3% in Q1 in response to inflation. The impact of inflation will reduce profits but on a relative basis, Unilever will become more attractive. 5 years of stagnation has left U...

My portfolio, built specifically for my retirement ~20+ years from now, makes a strong bet on a stock due for potential FDA approval in July. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valu...

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...

Arrowhead is a leader in RNAi. ARWR has a vast platform. I will wait for the first approval before investing. For further details see: Arrowhead Pharma: We Can Afford To Wait For More Proof

23andMe is a consumer-facing genetics testing company, one of the largest in terms of genetic databases. However, there are some glaring financial risks to consider if you want to invest in the company: slow test kit growth and profitability. New attempts to move towards drug deve...

Start Time: 09:45 End Time: 10:18 GSK plc (GSK) dbAcess Global Consumer Conference June 14, 2022, 09:45 AM ET Company Participants Tobias Hestler - CFO GSK Consumer Healthcare Conference Call Participants Tom Sykes - Deutsche Bank Presentation Tom Sykes Good afternoon, everybody, and thank yo...

Results from the phase 3 INFRONT-3 study using AL001 for the treatment of patients with Frontotemporal dementia are expected in 2023. Alector holds the potential to advance AL001 for both FTD-GRN and FTD-C9orf72 patients, plus several other neurological indications like Alzheimer's Di...

GSK has been a stalwart of stability in the healthcare sector, despite the lack of growth. Q2 2022 performance stood out, and performance has been strong across the board. The company is undergoing transformational changes that will make the investment proposition different, hopef...

GSK plc (GSK) Goldman Sachs 43rd Annual Global Healthcare Conference June 13, 2022, 05:00 PM ET Company Participants Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Kimberly Smith - Head of R&D, ViiV Healthcare Conference Call Participants Keyur Parekh - Goldman Sachs Presen...

Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. During a volatile quarter, the portfolio held up better than the Morningstar Global Markets ex-US Index...